Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, 26-week Multicenter Randomized Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study evaluated the efficacy and safety of two doses of indacaterol in adults aged 40 or over with chronic obstructive pulmonary disease (COPD) in China and in two other countries.


Options:
A: Arm Label: Indacaterol 75 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 75 μg | Arm Label: Placebo to indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 75 μg; Assigned to Arm(s): Indacaterol 75 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Placebo to indacaterol
B: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg, Drug: Placebo to salmeterol | Arm Label: Salmeterol 50 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 µg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Salmeterol 50 µg; Assigned to Arm(s): Salmeterol 50 µg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Salmeterol 50 µg | Intervention Type: DRUG; Name: Placebo to salmeterol; Assigned to Arm(s): Indacaterol 150 µg
C: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg | Arm Label: Indacaterol 300 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg | Arm Label: Placebo to indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Indacaterol 300 μg; Assigned to Arm(s): Indacaterol 300 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Placebo to indacaterol
D: Arm Label: Indacaterol 150 µg (Continued Into Stage 2); Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to Indacaterol, Drug: Placebo to Formoterol | Arm Label: Indacaterol 300 µg (Continued Into Stage 2); Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to Indacaterol, Drug: Placebo to Formoterol | Arm Label: Tiotropium 18 µg (Continued Into Stage 2); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium (18 µg o.d.) | Arm Label: Placebo (Continued Into Stage 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Formoterol | Arm Label: Indacaterol 75 µg (Not Continued into Stage 2); Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to Indacaterol, Drug: Placebo to Formoterol | Arm Label: Indacaterol 600 µg (Not Continued Into Stage 2); Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to Formoterol | Arm Label: Formoterol 12 µg (Not Continued Into Stage 2); Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol (12 µg b.i.d.), Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 150 µg (Continued Into Stage 2), Indacaterol 300 µg (Continued Into Stage 2), Indacaterol 600 µg (Not Continued Into Stage 2), Indacaterol 75 µg (Not Continued into Stage 2) | Intervention Type: DRUG; Name: Formoterol (12 µg b.i.d.); Assigned to Arm(s): Formoterol 12 µg (Not Continued Into Stage 2) | Intervention Type: DRUG; Name: Tiotropium (18 µg o.d.); Assigned to Arm(s): Tiotropium 18 µg (Continued Into Stage 2) | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Formoterol 12 µg (Not Continued Into Stage 2), Indacaterol 150 µg (Continued Into Stage 2), Indacaterol 300 µg (Continued Into Stage 2), Indacaterol 75 µg (Not Continued into Stage 2), Placebo (Continued Into Stage 2) | Intervention Type: DRUG; Name: Placebo to Formoterol; Assigned to Arm(s): Indacaterol 150 µg (Continued Into Stage 2), Indacaterol 300 µg (Continued Into Stage 2), Indacaterol 600 µg (Not Continued Into Stage 2), Indacaterol 75 µg (Not Continued into Stage 2), Placebo (Continued Into Stage 2)

Answer: C